Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Трансплантация сердца, наличие трансплантированного сердца, отмирание и отторжение трансплантата сердца

Список литературы

  1. Maddox T.M., Januzzi J.L., Allen L.A., et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021; 77 (6): 772– 810.
  2. McDonagh T.A., Metra M., Adamo M., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2021; 42 (36): 3599–3726.
  3. Готье С.В., Шевченко А.О., Кормер А.Я, Попцов В.Н., Саитгареев Р. Ш., Шумаков Д.В., Захаревич В.М. Три десятилетия трансплантации сердца в ФНЦ ТИО имени академика В.И. Шумакова: отдаленные результаты. Вестник трансплантологии и искусственных органов. 2015. Т. 15. № 2. С. 70-73.
  4. Lund et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report—2015. J Heart Lung Transplant 2015; 34:1244–1254.
  5. Готье С.В., Шевченко А.О., Попцов В.Н., Саитгареев Р.Ш., Захаревич В.М., Шумаков Д.В., Акопов Г.А. Опыт 800 трансплантаций сердца в НМИЦ трансплантологии и искусственных органов им. акад. В.И. Шумакова. Вестник трансплантологии и искусственных органов. 2017. Т. 19. № S. С. 52-53.
  6. Gautier SV, Shevchenko AO, et al. Thirty-Year Dynamics of Survival among Heart Recipients: A Single Center Russian Experience. Transplantation. 2018; 102: S827. DOI: 10.1097/01.tp.0000543875.50643.83.
  7. Клинические рекомендации «Хроническая сердечная недостаточность», одобрены Научно-практическим Советом Минздрава РФ в 2020. https://cr.minzdrav.gov.ru/schema/156_1#doc_a1
  8. Готье С.В., Шевченко А.О., Кормер А.Я., Попцов В.Н., Шевченко О.П. Перспективы улучшения отдаленных результатов трансплантации сердца. Вестник трансплантологии и искусственных органов. 2014. Т. XVI. № 3. С. 23-30.
  9. Готье C.В., Захаревич В.М., Халилулин Т.А, Шевченко А.О, Попцов В.Н, Р.Л. Ахмадзай, Гольц А.М., Закирьянов А.Р., Колоскова Н.Н., Захаревич Н.Ю., Никитина Е.А., Поздняков О.А., Кирьяков К.С. Трансплантация сердца как радикальный метод восстановление качества жизни у реципиентов с терминальной стадии сердечной недостаточности. Вестник трансплантологии и искусственных органов. 2019. Т. XXI. № 2. С. 70-73.
  10. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006;113:1424-33.
  11. Goda A, Williams P, Mancini D, Lund LH. Selecting patients for heart transplantation: comparison of the Heart Failure Survival Score (HFSS) and the Seattle heart failure model (SHFM). J Heart Lung Transplant 2011;30:1236-43.
  12. Levy WC, Mozaffarian D, Linker DT, Farrar DJ, Miller LW. Can the Seattle heart failure model be used to risk-stratify heart failure patients for potential left ventricular assist device therapy? J Heart Lung Transplant 2009;28:231-6.
  13. Kalogeropoulos AP, Georgiopoulou VV, Giamouzis G, et al. Utility of the Seattle Heart Failure Model in patients with advanced heart failure. J Am Coll Cardiol 2009;53:334-42.
  14. Herz M I. The Registry of the International Society for Heart and Lung Transplantation-- Introduction to the 2012 annual reports: new leadership, same vision. J Heart Lung Transplant. 2012;31:1045–1051.
  15. Arias M, Rush D N, Wiebe C, Gibson I W, Blydt-Hansen T D, Nickerson P W. et al. Antibody-mediated rejection: analyzing the risk, proposing solutions. Transplantation. 2014;98:3–21.[(Suppl 3)].
  16. Mehra M R. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant. 2006; 6:1248–1256.
  17. Mitchell R N, Libby P. Vascular remodeling in transplant vasculopathy. Circ Res. 2007;100:967–978.
  18. Tuzcu E M, Kapadia S R, Sachar R, Ziada K M, Crowe T D, Feng J. et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol. 2005;45:1538–1542.
  19. Goda A, Williams P, Mancini D, Lund LH. Selecting patients for heart transplantation: comparison of the Heart Failure Survival Score (HFSS) and the Seattle heart failure model (SHFM). J Heart Lung Transplant 2011; 30: 1236-43.
  20. Patel P., Glumova A., LaPorte K., Mahle W.T., Deshpande S.R. High Pulmonary Vascular Resistance in Pediatric Heart Transplant Patients and Role of Sildenafil. The Journal of Heart and Lung Transplantation, Vol. 36, Issue 4, S270.
  21. Ardehali A, Hughes K, Sadeghi A, et al. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation 2001;72:638-41.
  22. Auler Junior JO, Carmona MJ, Bocchi EA, et al. Low doses of inhaled nitric oxide in heart transplant recipients. J Heart Lung Transplant 1996;15:443-50.
  23. De Santo LS, Mastroianni C, Romano G, et al. Role of sildenafil in acute posttransplant right ventricular dysfunction: successful experience in 13 consecutive patients. Transplant Proc 2008;40:2015-8.
  24. Mikus E, Stepanenko A, Krabatsch T, et al. Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients. Eur J Cardiothorac Surg 2011; 40: 971-7.
  25. Kutty RS, Parameshwar J, Lewis C, et al. Use of centrifugal left ventricular assist device as a bridge to candidacy in severe heart failure with secondary pulmonary hypertension. Eur J Cardiothorac Surg 2013; 43:1237-42.
  26. Попцов В.Н., Спирина Е.А., Ухренков С.Г., Алиев Э.З., Хатуцкий В.М., Догонашева А.А. Механическая поддержка кровообращения при ранней дисфункции сердечного трансплантата. Вестник трансплантологии и искусственных органов. 2017. Т. 19. № S. С. 58.
  27. Готье С.В., Попцов В.Н., Захаревич В.М., Шевченко А.О., Спирина Е.А., Ухренков С.Г., Масютин С.А., Алиев Э.З., Воронков В.Ю., Чибисов Н.С., Устин С.Ю., Бондаренко Д.М. Пятилетний опыт применения периферической вено-артериальной экстракорпоральной мембранной оксигенации как метода механической поддержки кровообращения у потенциальных реципиентов сердца.// Вестник трансплантологии и искусственных органов. 2016. Т. 18. № 4. С. 16-25.
  28. Попцов В.Н., Спирина Е.А., Ухренков С.Г., Бондаренко Д.М., Догонашева А.А., Алиев Э.З. Временная механическая поддержка кровообращения у потенциальных реципиентов сердца. Вестник трансплантологии и искусственных органов. 2017. Т. 19. № 4. С. 113-123.
  29. Готье С.В., Попцов В.Н., Спирина Е.А., Саитгареев Р.Ш., Захаревич В.М., Акопов Г.А., Шумаков Д.В., Закирьянов А.Р., Халилулин Т.А., Гольц А.М., Шевченко А.О., Колоскова Н.Н. Сравнительный анализ факторов, потенциально влияющих на результаты трансплантации сердца, в группах пациентов, ранее оперированных на открытом сердца и ранее не оперированных. Вестник трансплантологии и искусственных органов. 2017. Т. 19. № S. С. 55-56.
  30. Готье С.В., Попцов В.Н., Саитгареев Р.Ш., Шумаков Д.В., Акопов Г.А., Тарабарко Н.Н., Анискевич Г.В. Пересадка сердца после коррекции клапанной патологии сердечного трансплантата.// Вестник трансплантологии и искусственных органов. 2017. Т. 19. № S. С. 65-66.
  31. Попцов В.Н., Спирина Е.А., Масютин С.А., Пчельников В.В., Ухренков С.Г., Алиев Э.З., Устин С.Ю., Хатуцкий В.М., Догонашева А.А. Периоперационный период при трансплантации сердца от доноров 55 лет и старше. Вестник трансплантологии и искусственных органов. 2017. Т. 19. № S. С. 62.
  32. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report — 2007. J Heart Lung Transplant 2007;26:769.
  33. Taylor DO, Stehlik J, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult heart transplant report — 2009. J Heart Lung Transplant 2009;28:1007.
  34. Leprince P, Aubert S, Bonnet N, et al. Peripheral extracorporeal membrane oxygenation (ECMO) in patients with posttransplant cardiac graft failure. Transplant Proc 2005;37:2879.
  35. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Waltz DA, Keck BM, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-third official adult heart transplantation report-2006. JHLTX 2006; 25:869-79.
  36. Gardner RS, McDanagh TA, MacDonald M, Dargie HJ, Murday AJ, Petrie MC. Who needs a heart transplant? Eur Heart J 2006; 27:770-2.
  37. Hunt SA, Kouretas PC, Balsam LB, Robbins RC. Heart transplantation. In Zipes DP, Libby P, Bonow RO, Braunwald E. Braunwald’s Heart Disease. 7 th edition. Elsevier Saunders 2005.
  38. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344 :1651-8.
  39. Lewis EF, Tsang SW, Fang JC, et al. Frequency and impact of delayed decisions regarding heart transplantation on long-term outcomes in patients with advanced heart failure. J Am Coll Cardiol 2004; 43:794-802.
  40. Feldman D. et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support. The Journal of Heart and Lung Transplantation, 2013 Vol. 32, Issue 2, p157–187.
  41. Иткин Г.П., Попцов В.Н. Механизмы правожелудочковой недостаточности в условиях левожелудочкового вспомогательного кровообращения и методы бивентрикулярного обхода сердца. Вестник трансплантологии и искусственных органов. 2013. Т. X . № 4. С. 126-135.
  42. Kirklin J.K., Naftel D.C., Pagani F.D., et al. Seventh INTERMACS annual report: 15,000 patients and counting. J. Heart Lung Transplant. 2015; 34: 1495– 1504.
  43. Готье С.В., Иткин Г.П., Шемакин С.Ю., Саитгареев Р.Ш, Попцов В.Н., Захаревич В.М., Акопов Г.А., Кормер А.Я., Халилулин Т.А., Шевченко О.П., Невзоров А.М., Филатов И.А., Селищев С.В. Первый опыт клинического применения отечественного аппарата вспомогательного кровообращения на базе имплантируемого осевого насоса для двухэтапной трансплантации сердца. Вестник трансплантологии и искусственных органов. 2013. Т. X . № 3. С. 92-101
  44. Taylor Clare J, Ordóñez-Mena José M, Roalfe Andrea K, Lay-Flurrie Sarah, Jones Nicholas R, Marshall Tom et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study BMJ 2019; 364 :l223
  45. Brown KN, Kanmanthareddy A. Heart Transplantation Patient Selection. [Updated 2020 Oct 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan- Available from: https://www.ncbi.nlm.nih.gov/books/NBK537090/.
  46. Ravichandran AK, Cowger J. Left ventricular assist device patient selection: do risk scores help?. J Thorac Dis. 2015;7(12):2080-2087. doi:10.3978/j.issn.2072-1439.2015.11.02
  47. S. Li, et al.Validity of the Seattle Heart Failure Model after heart failure hospitalization. ESC Heart Fail., 6 (3) (2019), pp. 509-515.
  48. Gorodeski EZ, Chu EC, Chow CH, Levy WC, Hsich E, Starling RC. Application of the Seattle Heart Failure Model in ambulatory patients presented to an advanced heart failure therapeutics committee. Circ Heart Fail 2010;3:706-14.
  49. Pamboukian SV, Tallaj JA, Brown RN, et al. Comparison of observed survival with assist device versus predicted survival without device using the Seattle heart failure model. ASAIO J 2012;58:93-7.
  50. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997;95:2660-7.
  51. Parikh MN, Lund LH, Goda A, Mancini D. Usefulness of peak exercise oxygen consumption and the heart failure survival score to predict survival in patients 465 years of age with heart failure. Am J Cardiol 2009;103:998-1002.
  52. Goda A, Lund LH, Mancini DM. Comparison across races of peak oxygen consumption and heart failure survival score for selection for cardiac transplantation. Am J Cardiol 2010;105:1439-44.
  53. Green P, Lund LH, Mancini D. Comparison of peak exercise oxygen consumption and the Heart Failure Survival Score for predicting prognosis in women versus men. Am J Cardiol 2007;99:399-403.
  54. Lund LH, Aaronson KD, Mancini DM. Validation of peak exercise oxygen consumption and the Heart Failure Survival Score for serial risk stratification in advanced heart failure. Am J Cardiol 2005;95:734-41.
  55. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778-86.
  56. Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates—2006. J Heart Lung Transplant 2006;25:1024-42.
  57. Stevenson LW, Miller LW, Desvigne-Nickens P, et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation 2004;110:975-81.
  58. Hershberger RE, Nauman D, Walker TL, Dutton D, Burgess D. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail 2003;9:180-7.
  59. Fellahi J.L. et al. Perioperative Use of Dobutamine in Cardiac Surgery and Adverse Cardiac Outcome: Propensity-adjusted Analyses. Anesthesiology. 2008; 108: 979–987.
  60. Rao V, Oz MC, Flannery MA, Catanese KA, Argenziano M, Naka Y. Revised screening scale to predict survival after insertion of a left ventricular assist device. J Thorac Cardiovasc Surg 2003;125:855-62.
  61. Lietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 2007;116:497-505.
  62. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-29.
  63. Schaffer JM, Allen JG, Weiss ES, et al. Evaluation of risk indices in continuous-flow left ventricular assist device patients. Ann Thorac Surg 2009;88:1889-96.
  64. Teuteberg J, Ewald G, Adamson R, et al. Application of the destination therapy risk score to HeartMate II clinical trial data [abstract] [manuscript in press, JACC]. J Heart Lung Transplant 2011;30:S31.
  65. Boyle AJ, Ascheim DD, Russo MJ, et al. Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification. J Heart Lung Transplant 2011;30:402-7.
  66. Cowger J, Sundareswaran K, Rogers J, et al. The HeartMate II risk score: Predicting survival in candidates for left ventricular assist device support [abstract]. J Heart Lung Transplant 2011;30:S31
  67. S.G. Al Kindi, M. Farhoud, et al. Left ventricular assist devices or inotropes for decreasing pulmonary vascular resistance in patients with pulmonary hypertension listed for heart transplantation J. Card. Fail., 23 (2017), pp. 209-215.
  68. Jennifer Cowger et al. 70 The HeartMate II Risk Score: Predicting Survival in Candidates for Left Ventricular Assist Device Support. April 2011The Journal of Heart and Lung Transplantation 30(4).
  69. Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 2009;54:312-21.
  70. Goodwin M, Nemeh HW, Borgi J, Paone G, Morgan JA. Resolution of Mitral Regurgitation With Left Ventricular Assist Device Support Ann Thorac Surg. 2017 Sep;104(3):811-818.
  71. Schweiger M1, Stepanenko A, Vierecke J, Drews T, Potapov E, Hetzer R, Krabatsch T. Biological mitral valve prosthesis in a patient supported with a permanent left ventricle assist device. ASAIO J. 2011 Nov-Dec;57(6):550-2.
  72. Choi JH, Luc JGY, Moncho Escrivá E, Phan K, Rizvi SSA, Patel S, Entwistle JW, Morris RJ, Massey HT, Tchantchaleishvili V. Impact of Concomitant Mitral Valve Surgery With LVAD Placement: Systematic Review and Meta-Analysis Artif Organs. 2018 Dec;42(12):1139- 1147
  73. Oezpeker C, Zittermann A, Paluszkiewicz L, Piran M, Puehler T, Sayin AO, Ensminger S, Milting H, Morshuis M, Gummert JF. Tricuspid valve repair in patients with left-ventricular assist device implants and tricuspid valve regurgitation: propensity score-adjusted analysis of clinical outcome. Interact Cardiovasc Thorac Surg. 2015 Dec;21(6):741-7
  74. Lahpor JR, de Jonge N, van Swieten HA, Wesenhagen H, Klöpping C, Geertman JH, Oosterom A, Rodermans B, Kirkels JH.Left ventricular assist device as bridge to transplantation in patients with end-stage heart failure: Eight-year experience with the implantable HeartMate LVAS. Neth Heart J. 2002 Jun;10(6):267-271
  75. Morgan JA, Tsiouris A, Nemeh HW, Hodari A, Karam J, Brewer RJ, Paone G. Impact of concomitant cardiac procedures performed during implantation of long-term left ventricular assist devices. J Heart Lung Transplant. 2013 Dec;32(12):1255-61
  76. Kittipibul V, Rattanawong P, Kewcharoen J, Chongsathidkiet P, Vutthikraivit W, Kanjanahattakij N. Atrial Fibrillation Is Not Associated With Thromboembolism in Left Ventricular Assist Device Patients: A Systematic Review and Meta-Analysis. ASAIO J. 2018 Jun 5
  77. Johnsson P, Algotsson L, Ryding E, Stahl E, Messeter K. Cardiopulmonary perfusion and cerebral blood flow in bilateral carotid artery disease. Ann Thorac Surg 1991;51:579-84.
  78. Selim M. Angioplasty and stenting of asymptomatic carotid stenosis before cardiac surgery: more study is needed. Arch Neurol 2008; 65:1672-4.
  79. Lazar HL, Menzoian JO. Coronary artery bypass grafting in patients with cerebrovascular disease. Ann Thorac Surg 1998;66:968-74.
  80. Kato TS, Schulze PC, Yang J, et al. Pre-operative and post-operative risk factors associated with neurologic complications in patients with advanced heart failure supported by a left ventricular assist device. J Heart Lung Transplant 2012;31:1-8.
  81. Wadia Y, Etheridge W, Smart F, Wood RP, Frazier OH. Pathophysiology of hepatic dysfunction and intrahepatic cholestasis in heart failure and after left ventricular assist device support. J Heart Lung Transplant 2005;24:361-70.
  82. Levy JH, Winkler AM. Heparin-induced thrombocytopenia and cardiac surgery. Curr Opin Anaesthesiol 2010;23:74-9.
  83. Morel-Kopp MC, Aboud M, Tan CW, Kulathilake C, Ward C. Whole blood impedance aggregometry detects heparin-induced thrombocytopenia antibodies. Thromb Res 2010;125:e234-9.
  84. Warkentin TE, Greinacher A, Koster A. Heparin-induced thrombocytopenia in patients with ventricular assist devices: are new prevention strategies required? Ann Thorac Surg 2009;87:1633-40.
  85. Zucker MJ, Sabnani I, Baran DA, Balasubramanian S, Camacho M. Cardiac transplantation and/or mechanical circulatory support device placement using heparin anti- coagulation in the presence of acute heparin-induced thrombocytopenia. J Heart Lung Transplant 2010;29:53-60.
  86. Butler J, Howser R, Portner PM, Pierson RN 3rd. Diabetes and outcomes after left ventricular assist device placement. J Card Fail 2005;11:510-5.
  87. Topkara VK, Dang NC, Martens TP, et al. Effect of diabetes on short- and long-term outcomes after left ventricular assist device implantation. J Heart Lung Transplant 2005;24:2048-53.
  88. Uriel N, Naka Y, Colombo PC, et al. Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices. Eur J Heart Fail 2011;13:195-9.
  89. Kolesar A, Sabol F, Luczy J, Bajmoczi M. Use of left ventricle assist device in a pregnant woman with acute aortic and coronary dissections. Interact Cardiovasc Thorac Surg 2010;11:194-5.
  90. LaRue S, Shanks A, Wang IW, Ewald G, Anderson D, Joseph S. Left ventricular assist device in pregnancy. Obstet Gynecol 2011;118: 426-8.
  91. Oles D, Berryessa R, Campbell K, Bhatti MA. Emergency redo mitral valve replacement in a 27-year-old pregnant female with a clotted prosthetic mitral valve, preoperative fetal demise and postoperative ventricular assist device: a case report. Perfusion 2001;16:159-64. The Journal of Heart and Lung Transplantation, Vol 32, No 2, February 2013 180
  92. Sims DB, Vink J, Uriel N, et al. A successful pregnancy during mechanical circulatory device support. J Heart Lung Transplant 2011;30:1065
  93. Dew MA, DiMartini AF, Steel J, et al. Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs. Liver Transpl 2008;14:159-72
  94. Holman WL, Kormos RL, Naftel DC, et al. Predictors of death and transplant in patients with a mechanical circulatory support device: a multi-institutional study. J Heart Lung Transplant 2009;28:44-50.
  95. Adamson RM, Stahovich M, Chillcott S, et al. Clinical strategies and outcomes in advanced heart failure patients older than 70 years of age receiving the HeartMate II left ventricular assist device: a community hospital experience. J Am Coll Cardiol 2011;57:2487-95.
  96. Park SJ, Milano CA, Tatooles AJ, et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail 2012;5:241-8
  97. Raymond AL, Kfoury AG, Bishop CJ, et al. Obesity and left ventricular assist device driveline exit site infection. ASAIO J 2010;56:57-60.
  98. Zahr F, Genovese E, Mathier M, et al. Obese patients and mechanical circulatory support: weight loss, adverse events, and outcomes. Ann Thorac Surg 2011;92:1420-6.

  1. Brewer RJ, Lanfear DE, Sai-Sudhakar CB, et al. Extremes of body mass index do not impact mid-term survival after continuous-flow left ventricular assist device implantation. J Heart Lung Transplant 2012;31:167-72
  2. Gelow JM, Desai AS, Hochberg CP, Glickman JN, Givertz MM, Fang JC. Clinical predictors of hepatic fibrosis in chronic advanced heart failure. Circ Heart Fail 2010;3:59-64.
  3. Matthews JC, Pagani FD, Haft JW, Koelling TM, Naftel DC, Aaronson KD. Model for end-stage liver disease score predicts left ventricular assist device operative transfusion requirements, morbidity, and mortality. Circulation 2010;121:214-20.
  4. Concha PM, Mertz KV. [Perioperative risk among patients with cirrhosis]. Rev Med Chil 2010;138:1165-71.
  5. Modi A, Vohra HA, Barlow CW. Do patients with liver cirrhosis undergoing cardiac surgery have acceptable outcomes? Interact Cardiovasc Thorac Surg 2010;11:630-4.
  6. Frazier OH, Rose EA, Oz MC, et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 2001; 122:1186-95.
  7. Khan MA, Hussain SF. Pre-operative pulmonary evaluation. J Ayub Med Coll Abbottabad 2005;17:82-6.
  8. Wright DJ, Khan KM, Gossage EM, Saltissi S. Assessment of a low-intensity cardiac rehabilitation programme using the six-minute walk test. Clin Rehabil 2001;15:119-24.
  9. Smetana GW. Preoperative pulmonary evaluation. N Engl J Med 1999;340:937-44.
  10. Smetana GW, Lawrence VA, Cornell JE. Preoperative pulmonary risk stratification for noncardiothoracic surgery: systematic review for the American College of Physicians. Ann Intern Med 2006;144:581-95.
  11. Miller LW, Lietz K. Candidate selection for long-term left ventricular assist device therapy for refractory heart failure. J Heart Lung Transplant 2006;25:756-64.
  12. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Respir J 2005;26:153-61.
  13. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948-68.
  14. Rady MY, Ryan T. Perioperative predictors of extubation failure and the effect on clinical outcome after cardiac surgery. Crit Care Med 1999;27:340-7.
  15. Samuels LE, Kaufman MS, Morris RJ, Promisloff R, Brockman SK. Coronary artery bypass grafting in patients with COPD. Chest 1998; 113:878-82.

  1. Dimick JB, Chen SL, Taheri PA, Henderson WG, Khuri SF, Campbell DA Jr.. Hospital costs associated with surgical complications: a report from the private-sector National Surgical Quality Improvement Program. J Am Coll Surg 2004;199:531-7.
  2. Bapoje SR, Whitaker JF, Schulz T, Chu ES, Albert RK. Preoperative evaluation of the patient with pulmonary disease. Chest 2007; 132:1637-45.
  3. Arozullah AM, Daley J, Henderson WG, Khuri SF. Multifactorial risk index for predicting postoperative respiratory failure in men after major noncardiac surgery. The National Veterans Administration Surgical Quality Improvement Program. Ann Surg 2000;232:242-53.
  4. Canet J, Gallart L, Gomar C, et al. Prediction of postoperative pulmonary complications in a population-based surgical cohort. Anesthesiology 2010;113:1338-50.
  5. Kroenke K, Lawrence VA, Theroux JF, Tuley MR, Hilsenbeck S. Postoperative complications after thoracic and major abdominal surgery in patients with and without obstructive lung disease. Chest 1993;104:1445-51.
  6. Culver BH. How should the lower limit of the normal range be defined? Respir Care 2012;57:136-45.
  7. Sandner SE, Zimpfer D, Zrunek P, et al. Renal function and outcome after continuous flow left ventricular assist device implantation. Ann Thorac Surg 2009;87:1072-8.
  8. Butler J, Geisberg C, Howser R, et al. Relationship between renal function and left ventricular assist device use. Ann Thorac Surg 2006;81:1745-51.
  9. Topkara VK, Dang NC, Barili F, et al. Predictors and outcomes of continuous veno- venous hemodialysis use after implantation of a left ventricular assist device. J Heart Lung Transplant 2006;25:404-8.
  10. Ootaki C, Yamashita M, Ootaki Y, et al. Reduced pulsatility induces periarteritis in kidney: role of the local renin-angiotensin system. J Thorac Cardiovasc Surg 2008;136:150-8.
  11. Radovancevic B, Vrtovec B, de KE, Radovancevic R, Gregoric ID, Frazier OH. End- organ function in patients on long-term circulatory support with continuous- or pulsatile-flow assist devices. J Heart Lung Transplant 2007;26:815-8.
  12. Letsou GV, Myers TJ, Gregoric ID, et al. Continuous axial-flow left ventricular assist device (Jarvik 2000) maintains kidney and liver perfusion for up to 6 months. Ann Thorac Surg 2003;76:1167-70.
  13. Russell SD, Rogers JG, Milano CA, et al. Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. Circulation 2009;120:2352-7.

  1. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007;357:885-96.
  2. Slaughter MS, Pagani FD, Rogers JG, et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant 2010;29:S1-39.
  3. Singh M, Shullo M, Kormos RL, et al. Impact of renal function before mechanical circulatory support on posttransplant renal outcomes. Ann Thorac Surg 2011;91:1348-54.
  4. Cupples S, Dew MA, Grady KL, et al. Report of the Psychosocial Outcomes Workgroup of the Nursing and Social Sciences Council of the International Society for Heart and Lung Transplantation: present status of research on psychosocial outcomes in cardiothoracic transplantation: review and recommendations for the field. J Heart Lung Transplant 2006;25:716-25.
  5. Eshelman AK, Mason S, Nemeh H, Williams C. LVAD destination therapy: applying what we know about psychiatric evaluation and management from cardiac failure and transplant. Heart Fail Rev 2009;14:21-8.
  6. Levenson JL, Olbrisch ME. Psychosocial evaluation of organ transplant candidates. A comparative survey of process, criteria, and outcomes in heart, liver, and kidney transplantation. Psychosomatics 1993;34:314-23.
  7. Olbrisch ME, Benedict SM, Ashe K, Levenson JL. Psychological assessment and care of organ transplant patients. J Consult Clin Psychol 2002;70:771-83.
  8. Olbrisch ME, Levenson JL. Psychosocial assessment of organ transplant candidates. Current status of methodological and philosophical issues. Psychosomatics 1995;36:236-43.
  9. De Geest S, Abraham I, Moons P, et al. Late acute rejection and subclinical noncompliance with cyclosporine therapy in heart transplant recipients. J Heart Lung Transplant 1998;17:854-63.
  10. De Geest S, Dobbels F, Martin S, Willems K, Vanhaecke J. Clinical risk associated with appointment noncompliance in heart transplant recipients. Prog Transplant 2000;10:162-8.
  11. De Geest S, Dobbels F, Fluri C, Paris W, Troosters T. Adherence to the therapeutic regimen in heart, lung, and heart-lung transplant recipients. J Cardiovasc Nurs 2005;20:S88-98.
  12. Dew MA, Roth LH, Thompson ME, Kormos RL, Griffith BP. Medical compliance and its predictors in the first year after heart transplantation. J Heart Lung Transplant 1996;15:631- 45.
  13. Nagele H, Kalmar P, Rodiger W, Stubbe HM. Smoking after heart transplantation: an underestimated hazard? Eur J Cardiothorac Surg 1997;12:70-4

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*